November 4, 2007 - Itamar Medical announced that four presentations at AHA, including one from the Framingham Heart Study, link PAT signal with several cardiovascular conditions and risk factors as the technology gains broader acceptance.
The Endo-PAT, developed by Itamar Medical, is a FDA approved noninvasive device that detects a pathology called endothelial dysfunction. The condition refers to an impairment of the endothelial layer and is emerging as a key precursor for the development of atherosclerosis.
The noninvasive Endo-PAT device, based on PAT technology, measures subtle but significant vaso-motion changes through a small thimble-like probe placed over a person's index finger. Tests administered with the Endo-PAT provide clinicians and researchers an effective tool for the detection of endothelial dysfunction. Early detection has the potential to reduce the medical and cost burden of cardiovascular disease. Valuable diagnostic information can be obtained from the Endo-PAT at a fraction of the cost of other established approaches which can only be administered by a skilled technician and even then are too operator dependent.
In addition to the data from the Framingham Heart Study, that showed in a large population base study an association between the Endo-PAT results and several risk factors, three other oral presentations from Britain and Sweden showed the relevancy of endothelial function assessment with the Endo-PAT in other conditions in children and adults.
Based on the new studies that support for Endo- PAT as a significant tool in the prevention and management of cardiovascular disease, combined with successful trials of the Endo-PAT at the Mayo Clinic, Harvard University and other academic medical centers, Itamar Medical is now ready to make Endo-PAT Technology available to clinicians beyond the research environment and into the general medical community.
For more information: www.itamar-medical.com
October 31, 2023 
